Clinical applications of quinolones

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1400, Issue 1-3, 1998, Pages 45-61

  Hooper, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

DNA gyrase; Infection; Pharmacology; Quinolone; Resistance; Topoisomerase IV

Indexed keywords

CIPROFLOXACIN; ENOXACIN; LOMEFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; SPARFLOXACIN;

ANAEROBIC BACTERIUM; ANTIMICROBIAL ACTIVITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; INFECTION; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE; ENZYME INHIBITORS; MOLECULAR STRUCTURE; QUINOLONES;

EID: 0032189757     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(98)00127-4     Document Type: Review

References (188)

1. Hooper D.C., Wolfson J.S. Fluoroquinolone antimicrobial agents. New Engl. J. Med. 324:1991;384-394.
2. Eliopoulos G.M. In vitro activity of fluoroquinolones against gram-positive bacteria. Drugs. 49:(Suppl. 2):1995;48-57.
3. Blumberg H.M., Rimland D., Carroll D.J., Terry P., Wachsmuth I.K. Rapid development of ciprofloxacin resistance in methicillin- susceptible and -resistant Staphylococcus aureus. J. Infect. Dis. 163:1991;1279-1285.
4. McCormack W.M. Susceptibility of mycoplasmas to antimicrobial agents: clinical implications. Clin. Infect. Dis. 17:(Suppl. 1):1993;S200-S201.
5. Arai S., Gohara Y., Kuwano K., Kawashima T. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 36:1992;1322-1324.
6. Kitsukawa K., Hara J., Saito A. Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents. J. Antimicrob. Chemother. 27:1991;343-353.
7. Meyer R.D. Role of the quinolones in the treatment of legionellosis. J. Antimicrob. Chemother. 28:1991;623-625.
8. Anonymous, Sparfloxacin and levofloxacin, Med. Lett. Drugs Ther. 39 (1997) 41-43.
9. Goa K.L., Bryson H.M., Markham A. Sparfloxacin - a review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs. 53:1997;700-725.
10. Johnson A.P., Speller D.C.E., Warner M., Domingue G. In-vitro activity of levofloxacin (L-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales. J. Antimicrob. Chemother. 38:1996;907-908.
11. Fu K.P., Lafredo S.C., Foleno B., Isaacson D.M., Barrett J.F., Tobia A.J., Rosenthale M.E. In vitro and in vivo antibacterial activities of levofloxacin (L-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. 36:1992;860-866.
12. Richard P., Gutmann L. Sparfloxacin and other new fluoroquinolones. J. Antimicrob. Chemother. 30:1992;739-744.
13. Gootz T.D., McGuirk P.R. New quinolones in development. Expert Opin. Invest. Drugs. 3:1994;93-114.
14. Yoshida H., Nakamura M., Bogaki M., Ito H., Kojima T., Hattori H., Nakamura S. Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob. Agents Chemother. 37:1993;839-845.
15. Sato K., Hoshino K., Mitsuhashi S. Mode of action of new quinolones: the inhibitory activity on DNA gyrase. Prog. Drug Res. 38:1992;121-132.
16. Hoshino K., Sato K., Une T., Osada Y. Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus. Antimicrob. Agents Chemother. 33:1989;1816-1818.
17. Hoshino K., Kitamura A., Morrissey I., Sato K., Kato J., Ikeda H. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob. Agents Chemother. 38:1994;2623-2627.
18. Hooper D.C., Wolfson J.S. Mode of action of the quinolone antimicrobial agents. Rev. Infect. Dis. 10:(Suppl. 1):1988;S14-S21.
19. N. Karabalut, G.L. Drusano, Pharmacokinetics of the quinolone antimicrobial agents, in: D.C. Hooper, J.S. Wolfson (Eds.), Quinolone Antimicrobial Agents, American Society for Microbiology, Washington, DC, 1993, pp. 195-244.
20. Stein G.E. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis. 23:1996;S19-S24.
21. von Rosenstiel N., Adam D. Quinolone antibacterials. An update of their pharmacology and therapeutic use. Drugs. 47:1994;872-901.
22. Fitton A. The quinolones. An overview of their pharmacology. Clin. Pharmacokinet. 22:(Suppl. 1):1992;1-11.
23. Dudley M.N. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am. J. Med. 91:1991;45S-50S.
24. Gerding D.N., Hitt J.A. Tissue penetration of the new quinolones in humans. Rev. Infect. Dis. 11:(Suppl. 5):1989;S1046-S1057.
25. Carlier M.B., Scorneaux B., Zenebergh A., Desnottes J.F., Tulkens P.M. Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages. J. Antimicrob. Chemother. 26:(Suppl. B):1990;27-39.
26. Sorgel F., Kinzig M. Pharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions. Am. J. Med. 94:1993;56S-69S.
27. Eliopoulos G.M. New quinolones: pharmacology, pharmacokinetics, and dosing in patients with renal insufficiency. Rev. Infect. Dis. 10:(Suppl. 1):1988;S102-S105.
28. Fish D.N., Chow A.T. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 32:1997;101-119.
29. Davis R., Bryson H.M. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs. 47:1994;677-700.
30. Lamp K.C., Bailey E.M., Rybak M.J. Ofloxacin clinical pharmacokinetics. Clin. Pharmacokinet. 22:1992;32-46.
31. Montay G. Pharmacokinetics of sparfloxacin in healthy volunteers and patients: a review. J. Antimicrob. Chemother. 37:1996;27-39.
32. D.E. Nix, Drug-drug interactions with fluoroquinolone antimicrobial agents, in: D.C. Hooper, J.S. Wolfson (Eds.), Quinolone Antimicrobial Agents, American Society for Microbiology, Washington, DC, 1993, pp. 245-258.
33. Prince R.A., Casabar E., Adair C.G., Wexler D.B., Lettieri J., Kasik J.E. Effect of quinolone antimicrobials on theophylline pharmacokinetics. J. Clin. Pharmacol. 29:1989;650-654.
34. Sano M., Kawakatsu K., Ohkita C., Yamamoto I., Takeyama M., Yamashina H., Goto M. Effects of enoxacin, ofloxacin and norfloxacin on theophylline disposition in humans. Eur. J. Clin. Pharmacol. 35:1988;161-165.
35. D.C. Hooper, J.S. Wolfson, Adverse effects, in: D.C. Hooper, J.S. Wolfson (Eds.), Quinolone Antimicrobial Agents, American Society for Microbiology, Washington, DC, 1993, pp. 489-512.
36. Gootz T.D., McGuirk P.R., Moynihan M.S., Haskell S.L. Placement of alkyl substituents on the C-7 piperazine ring of fluoroquinolones: dramatic differential effects on mammalian topoisomerase II and DNA gyrase. Antimicrob. Agents Chemother. 38:1994;130-133.
37. Moreau N.J., Robaux H., Baron L., Tabary X. Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II. Antimicrob. Agents Chemother. 34:1990;1955-1960.
38. Hussy P., Maass G., Tummler B., Grosse F., Schomburg U. Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob. Agents Chemother. 29:1986;1073-1078.
39. Elsea S.H., McGuirk P.R., Gootz T.D., Moynihan M., Osheroff N. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob. Agents Chemother. 37:1993;2179-2186.
40. Froelich-Ammon S.J., McGuirk P.R., Gootz T.D., Jefson M.R., Osheroff N. Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: stereospecificity of the eukaryotic enzyme. Antimicrob. Agents Chemother. 37:1993;646-651.
41. T.D. Gootz, N. Osheroff, Quinolones and eukaryotic topoisomerases, in: D.C. Hooper, J.S. Wolfson (Eds.), Quinolone Antimicrobial Agents, American Society for Microbiology, Washington, DC, 1993, pp. 139-160.
42. Elsea S.H., Osheroff N., Nitiss J.L. Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J. Biol. Chem. 267:1992;13150-13153.
43. Kohlbrenner W.E., Wideburg N., Weigl D., Saldivar A., Chu D.T. Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothiazoloquinolones A-65281 and A-65282. Antimicrob. Agents Chemother. 36:1992;81-86.
44. S. Hori, J. Shimada, Effects of quinolones on the central nervous system, in: D.C. Hooper, J.S. Wolfson (Eds.), Quinolone Antimicrobial Agents, American Society for Microbiology, Washington, DC, 1993, pp. 513-526.
45. Hori S., Shimada J., Saito A., Matsuda M., Miyahara T. Comparison of the inhibitory effect of new quinolones on gamma-aminobutyric acid receptor binding in the presence of antiinflammatory drugs. Rev. Infect. Dis. 11:1989;S1397-S1398.
46. A receptors by 4-quinolones. J. Antimicrob. Chemother. 31:1993;457-462.
47. Ferguson J. Fluoroquinolone photosensitization: a review of clinical and laboratory studies. Photochem. Photobiol. 62:1995;954-958.
48. Lowe N.J., Fakouhi T.D., Stern R.S., Bourget T., Roniker B., Swabb E.A. Photoreactions with a fluoroquinolone antimicrobial: evening versus morning dosing. Clin. Pharmacol. Ther. 56:1994;587-591.
49. Zabraniecki L., Negrier I., Vergne P., Arnaud M., Bonnet C., Bertin P., Treves R. Fluoroquinolone induced tendinopathy: report of 6 cases. J. Rheumatol. 23:1996;516-520.
50. Ribard P., Audisio F., Kahn M.F., De Bandt M., Jorgensen C., Hayem G., Meyer O., Palazzo E. Seven Achilles tendinitis including 3 complicated by rupture during fluoroquinolone therapy. J. Rheumatol. 19:1992;1479-1481.
51. Machida M., Kusajima H., Aijima H., Maeda A., Ishida R., Uchida H. Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals. Toxicol. Appl. Pharmacol. 105:1990;403-412.
52. Schaad U.B., Wedgwood J. Lack of quinolone-induced arthropathy in children. J. Antimicrob. Chemother. 30:1992;414-416.
53. Schaad U.B., Stoupis C., Wedgwood J., Tschaeppeler H., Vock P. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr. Infect. Dis. J. 10:1991;723-729.
54. Dupont H., Timsit J.F., Souweine B., Gachot B., Wolff M., Regnier B. Torsades de pointe probably related to sparfloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;350-351.
55. Jaillon P., Morganroth J., Brumpt I., Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J. Antimicrob. Chemother. 37:1996;161-167.
56. Corrado M.L., Struble W.E., Peter C., Hoagland V., Sabbaj J. Norfloxacin: review of safety studies. Am. J. Med. 82:1987;22-26.
57. Takayama S., Watanabe T., Akiyama Y., Ohura K., Harada S., Matsuhashi K., Mochida K., Yamashita N. Reproductive toxicity of ofloxacin. Arzneim. Forsch. Drug Res. 36:1986;1244-1248.
58. Grubbs N.C., Schultz H.J., Henry N.K., Ilstrup D.M., Muller S.M., Wilson W.R. Ciprofloxacin versus trimethoprim-sulfamethoxazole: treatment of community-acquired urinary tract infections in a prospective, controlled, double-blind comparison. Mayo Clin. Proc. 67:1992;1163-1168.
59. Hooton T.M., Johnson C., Winter C., Kuwamura L., Rogers M.E., Roberts P.L., Stamm W.E. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women. Antimicrob. Agents Chemother. 35:1991;1479-1483.
60. Hooton T.M., Latham R.H., Wong E.S., Johnson C., Roberts P.L., Stamm W.E. Ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis. Antimicrob. Agents Chemother. 33:1989;1308-1312.
61. Stamm W.E., Hooton T.M. Management of urinary tract infections in adults. New Engl. J. Med. 329:1993;1328-1334.
62. Pfau A., Sacks T.G. Single dose quinolone treatment in acute uncomplicated urinary tract infection in women. J. Urol. 149:1993;532-534.
63. Backhouse C.I., Matthews J.A. Single-dose enoxacin compared with 3-day treatment for urinary tract infection. Antimicrob. Agents Chemother. 33:1989;877-880.
64. Wolfson J.S., Hooper D.C. Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis. Antimicrob. Agents Chemother. 33:1989;1655-1661.
65. Bergeron M.G. Treatment of pyelonephritis in adults. Med. Clin. North Am. 79:1995;619-649.
66. Williams A.H., Gruneberg R.N. Ciprofloxacin and co-trimoxazole in urinary tract infection. J. Antimicrob. Chemother. 18:1986;107-110.
67. Fang G.D., Brennen C., Wagener M., Swanson D., Hilf M., Zadecky L., DeVine J., Yu V.L. Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob. Agents Chemother. 35:1991;1849-1855.
68. Murray P.R., Bratcher J.L., Niles A.C., Hampton C.M. In vitro activity of nine fluoroquinolone antibiotics against 200 strains of enterococci. Diag. Microbiol. Infect. Dis. 16:1993;83-85.
69. Vazquez J., Perri M.B., Thal L.A., Donabedian S.A., Zervos M.J. Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits. J. Antimicrob. Chemother. 32:1993;715-721.
70. Fish D.N., Rodvold K.A. Fluoroquinolone treatment of Enterococcus infection. Acta Clin. Belg. 26:1992;498-500.
71. Lewin C.S., Morrissey I., Smith J.T. The fluoroquinolones exert a reduced rate of kill against Enterococcus faecalis. J. Pharm. Pharmacol. 43:1991;492-494.
72. Milatovic D., Braveny I. Development of resistance during antibiotic therapy. Eur. J. Clin. Microbiol. 6:1987;234-244.
73. Brown E.M., Morris R., Stephenson R. The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection. J. Antimicrob. Chemother. 18:1986;123-127.
74. Preheim L.C., Cuevas T.A., Roccaforte J.S., Mellencamp M.A., Bittner M.J. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria. Am. J. Med. 82:1987;295-300.
75. Andriole V.T. Use of quinolones in treatment of prostatitis and lower urinary tract infections. Eur. J. Clin. Microbiol. Infect. Dis. 10:1991;342-350.
76. Schaeffer A.J., Darras F.S. The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. J. Urol. 144:1990;690-693.
77. Weidner W., Schiefer H.G., Dalhoff A. Treatment of chronic bacterial prostatitis with ciprofloxacin. Results of a one-year follow-up study. Am. J. Med. 82:1987;280-283.
78. Guibert J., Destree C., Konopka C., Acar J. Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria. Eur. J. Clin. Microbiol. 2:1986;247-248.
79. Remy G., Rouger C., Chavanet P., Bernard E., Dellamonica P., Portier H. Use of ofloxacin for prostatitis. Rev. Infect. Dis. 10:1988;S173-S174.
80. Ridgway G.L. Quinolones in sexually transmitted diseases. Drugs. 45:(Suppl. 3):1993;134-138.
81. Hooper D.C., Wolfson J.S. Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects. Antimicrob. Agents Chemother. 33:1989;1662-1667.
82. Hook E.W., Jones R.B., Martin D.H., Bolan G.A., Mroczkowski T.F., Neumann T.M., Haag J.J., Echols R. Comparison of ciprofloxacin and ceftriaxone as single-dose therapy for uncomplicated gonorrhea in women. Antimicrob. Agents Chemother. 37:1993;1670-1673.
83. Covino J.M., Cummings M., Smith B., Benes S., Draft K., McCormack W.M. Comparison of ofloxacin and ceftriaxone in the treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing strains. Antimicrob. Agents Chemother. 34:1990;148-149.
84. H. Moi, P. Morel, B. Gianotti, D. Barlow, I. Phillips Jean (1996) Comparative efficacy and safety of single oral doses of sparfloxacin versus ciprofloxacin in the treatment of acute gonococcal urethritis in men, J. Antimicrob. Chemother. 37 (Suppl. A) 115-122.
85. Abeyewickereme I., Senaratne L., Prithiviraj V.B. Rapid emergence of 4-fluoroquinolone resistance with associated decline in penicillinase-producing Neisseria gonorrhoeae in Colombo, Sri Lanka. Genitourin. Med. 72:1996;302-302.
86. Kam K.M., Wong P.W., Cheung M.M., Ng K.Y.H., Lo K.K. Quinolone-resistant Neisseria gonorrhoeae in Hong Kong. Sex. Transm. Dis. 23:1996;103-108.
87. Anonymous, Fluoroquinolone resistance in Neisseria gonorrhoeae-Colorado and Washington, Morbid. Mortal. Weekly Rep. 44 (1995) 761-764.
88. Knapp J.S., Ohye R., Neal S.W., Parekh M.C., Higa H., Rice R.J. Emerging in vitro resistance to quinolones in penicillinase-producing Neisseria gonorrhoeae strains in Hawaii. Antimicrob. Agents Chemother. 38:1994;2200-2203.
89. Anonymous, Sexually transmitted diseases treatment guidelines, Centers for Disease Control and Prevention, Morbid. Mortal. Weekly Rep. 42 (1993) 1-102.
90. Carlin E.M., Barton S.E. Azithromycin as a cost-effective treatment for nongonococcal urethritis in men. Sex. Transm. Dis. 24:1997;57-57.
91. Thorpe E.M. Jr., Stamm W.E., Hook E.W., Gall S.A., Jones R.B., Henry K., Whitworth G., Johnson R.B. Chlamydial cervicitis and urethritis: single dose treatment compared with doxycycline for seven days in community based practises. Genitourin. Med. 72:1996;93-97.
92. Fransen L., Avonts D., Piot P. Treatment of genital chlamydial infection with ofloxacin. Infection. 14:1986;S318-S320.
93. Nakata K., Maeda H., Fujii A., Arakawa S., Umezu K., Kamidono S. In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis. Antimicrob. Agents Chemother. 36:1992;188-190.
94. Phillips I., Dimian C., Barlow D., Moi H., Stolz E., Weidner W., Perea E. A comparative study of two different regimens of sparfloxacin versus doxycycline in the treatment of non-gonococcal urethritis in men. J. Antimicrob. Chemother. 37:1996;123-134.
95. Boslego J.W., Hicks C.B., Greenup R., Thomas R.J., Wiener H.A., Ciak J., Tramont E.C. A prospective randomized trial of ofloxacin vs. doxycycline in the treatment of uncomplicated male urethritis. Sex. Transm. Dis. 15:1988;186-191.
96. Naamara W., Plummer F.A., Greenblatt R.M., D'Costa L.J., Ndinya-Achola J.O., Ronald A.R. Treatment of chancroid with ciprofloxacin. A prospective, randomized clinical trial. Am. J. Med. 82:1987;317-320.
97. Arredondo J.L., Diaz V., Gaitan H., Maradiegue E., Oyarzún E., Paz R., Reynal J.L., Stamm W., Zambrano D. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. Clin. Infect. Dis. 24:1997;170-178.
98. Veller-Fornasa C., Tarantello M., Cipriani R., Guerra L., Peserico A. Effect of ofloxacin on Treponema pallidum in incubating experimental syphilis. Genitourin. Med. 86:1987;214-214.
99. DuPont H.L. Use of quinolones in the treatment of gastrointestinal infections. Eur. J. Clin. Microbiol. Infect. Dis. 10:1991;325-329.
100. Griffiths N.M., Hirst B.H., Simmons N.L. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J. Pharmacol. Exp. Ther. 269:1994;496-502.
101. Dryden M.S., Gabb R.J.E., Wright S.K. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin. Infect. Dis. 22:1996;1019-1025.
102. Petruccelli B.P., Murphy G.S., Sanchez J.L., Walz S., DeFraites R., Gelnett J., Haberberger R.L., Echeverria P., Taylor D.N. Treatment of travelers' diarrhea with ciprofloxacin and loperamide. J. Infect. Dis. 165:1992;557-560.
103. Goodman L.J., Trenholme G.M., Kaplan R.L., Segreti J., Hines D., Petrak R., Nelson J.A., Mayer K.W., Landau W., Parkhurst G.W. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch. Intern. Med. 150:1990;541-546.
104. Neill M.A., Opal S.M., Heelan J., Giusti R., Cassidy J.E., White R., Mayer K.H. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann. Intern. Med. 114:1991;195-199.
105. Bennish M.L., Salam M.A., Haider R., Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J. Infect. Dis. 162:1990;711-716.
106. Bennish M.L., Salam M.A., Khan W.A., Khan A.M. Treatment of shigellosis: III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann. Intern. Med. 117:1992;727-734.
107. Murphy G.S. Jr., Echeverria P., Jackson L.R., Arness M.K., LeBron C., Pitarangsi C. Ciprofloxacin- and azithromycin-resistant Campylobacter causing travelers' diarrhea in US troops deployed to Thailand in 1994. Clin. Infect. Dis. 22:1996;868-869.
108. Segreti J., Gootz T.D., Goodman L.J., Parkhurst G.W., Quinn J.P., Martin B.A., Trenholme G.M. High-level quinolone resistance in clinical isolates of Campylobacter jejuni. J. Infect. Dis. 165:1992;667-670.
109. Endtz H.P., Ruijs G.J., van Klingeren B., Jansen W.H., van der Reyden T., Mouton R.P. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J. Antimicrob. Chemother. 27:1991;199-208.
110. Rademaker C.M., Hoepelman I.M., Wolfhagen M.J., Beumer H., Rozenberg-Arska M., Verhoef J. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travelers' diarrhea. Eur. J. Clin. Microbiol. Infect. Dis. 8:1989;690-694.
111. Wiström J., Jertborn M., Ekwall E., Norlin K., Soderquist B., Stromberg A., Lundholm R., Hogevik H., Lagergren L., Englund G. Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. Ann. Intern. Med. 117:1992;202-208.
112. Smith M.D., Duong N.M., Hoa N.T., Wain J., Ha H.D., Diep T.S., Day N.P., Hien T.T., White N.J. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob. Agents Chemother. 38:1994;1716-1720.
113. Dutta P., Rasaily R., Saha M.R., Mitra U., Bhattacharya S.K., Bhattacharya M.K., Lahiri M. Ciprofloxacin for treatment of severe typhoid fever in children. Antimicrob. Agents Chemother. 37:1993;1197-1199.
114. Wang F., Gu X.J., Zhang M.F., Tai T.Y. Treatment of typhoid fever with ofloxacin. J. Antimicrob. Chemother. 23:1989;785-788.
115. Hoge C.W., Bodhidatta L., Tungtaem C., Echeverria P. Emergence of nalidixic acid resistant Shigella dysenteriae type 1 in Thailand: An outbreak associated with consumption of a coconut milk dessert. Int. J. Epidemiol. 24:1995;1228-1232.
116. Rahman M., Mauff G., Levy J., Couturier M., Pulverer G., Glasdorff N., Butzler J.P. Detection of 4-quinolone resistance mutation in gyrA gene of Shigella dysenteriae type 1 by PCR. Antimicrob. Agents Chemother. 38:1994;2488-2491.
117. Pons J.L., Mandement M.N., Martin E., Lemort C., Nouvellon M., Mallet E., Lemeland J.F. Clonal and temporal patterns of nasopharyngeal penicillin- susceptible and penicillin-resistant Streptococcus pneumoniae strains in children attending a day care center. J. Clin. Microbiol. 34:1996;3218-3222.
118. Friedland I.R. Therapy of penicillin- and cephalosporin-resistant pneumococcal infections. Ann. Med. 25:1993;451-455.
119. Wolfson J.S., Hooper D.C. Fluoroquinolone antimicrobial agents. Clin. Microbiol. Rev. 2:1989;378-424.
120. Chrysanthopoulos C.J., Starakis J.C., Skoutelis A.T., Bassaris H.P. Sequential intravenous/oral therapy with ciprofloxacin in severe infection. Am. J. Med. 87:1989;225S-227S.
121. Gentry L.O., Rodriguez-Gomez G., Kohler R.B., Khan F.A., Rytel M.W. Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. Am. Rev. Resp. Dis. 145:1992;31-35.
122. Sanders W.E. Jr., Morris J.F., Alessi P., Makris A.T., McCloskey R.V., Trenholme G.M., Iannini P., Bittner M.J. Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with 'usual care' in a multicenter clinical trial. Am. J. Med. 91:1991;261-266.
123. H. Portier, T. May, A. Proust, N. Tolstuchow, J.F. Muir, P. Balmes, Paganin, P. Carles, F. Blanchon, J. Rochemaure, A.B. Tonnel, P. Dumont, C. Wallaert, J.M. Ragnaud, B. Becq-Giraudon, G. Nouvet, E. Weitzenblum, B. Leng, J. Gaillat, C. Defouilloy, A. Arnaud, B. Herer, G. Miech J. Modai, Comparative efficacy of sparfloxacin in comparison with amoxycillin plus ofloxacin in the treatment of community-acquired pneumonia, J. Antimicrob. Chemother. 37 (1996) 83-91.
124. Örtqvist Å., Valtonen M., Cars O., Wahl M., Saikku P., Jean C., Holmen C., Werner M., Stenlund G., Danielsson A., Hagberg L., Nilsson B.O., Nyström G., Augustinsson Å., Otto G., Ljungström L., Boman H., Hebelka M., Odenholdt I., Schönbeck C., Hjalt C.Å., Leinonen M., Harno K., Kyrönseppä H. Oral empiric treatment of community-acquired pneumonia - a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest. 110:1996;1499-1506.
125. M.P. Fink, D.R. Snydman, M.S. Niederman, K.V. Leeper Jr., R.H. Johnson, S.O. Heard, R.G. Wunderink, J.W. Caldwell, Schentag, J.J., G.A. Siami, R.L. Zameck, D.C. Haverstock, H.H. Reinhart, R.M. Echols, Severe Pneumonia Study Group, Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin, Antimicrob. Agents Chemother. 38 (1994) 547-557.
126. Peloquin C.A., Cumbo T.J., Nix D.E., Sands M.F., Schentag J.J. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch. Intern. Med. 149:1989;2269-2273.
127. Jensen T., Pedersen S.S., Nielsen C.H., Hoiby N., Koch C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J. Antimicrob. Chemother. 20:1987;585-594.
128. Hodson M.E., Roberts C.M., Butland R.J., Smith M.J., Batten J.C. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet. 1:1987;235-237.
129. Roberts C.M., Batten J., Hodson M.E. Ciprofloxacin-resistant Pseudomonas. Lancet. 1:1985;1442.
130. Leysen D.C., Haemers A., Pattyn S.R. Mycobacteria and the new quinolones. Antimicrob. Agents Chemother. 33:1989;1-5.
131. Kennedy N., Berger L., Curram J., Fox R., Gutmann J., Kisyombe G.M., Ngowi F.I., Ramsay A.R.C., Saruni A.O.S., Sam N., Tillotson G., Uiso L.O., Yates M., Gillespie S.H. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clin. Infect. Dis. 22:1996;827-833.
132. Kohno S., Koga H., Kaku M., Maesaki S., Hara K. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest. 102:1992;1815-1818.
133. Hass D.W., McAndrew M.P. Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment. Am. J. Med. 101:1996;550-561.
134. P.M. Mertes, P. Voiriot, C. Dopff, H. Scholl, M. Clavey, J.P. Villemot, Canton, J.B. Dureux, Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans, Antimicrob. Agents Chemother. 34 (1990) 398-401.
135. Lew D.P., Waldvogel F.A. Quinolones and osteomyelitis: state-of-the-art. Drugs. 49:(Suppl. 2):1995;100-111.
136. G.M. Eliopoulos, C.T. Eliopoulos, Activity in vitro of the quinolones, in: D.C. Hooper, J.S. Wolfson (Eds.), Quinolone Antimicrobial Agents, American Society for Microbiology, Washington, DC, 1993, pp. 161-193.
137. Gentry L.O., Rodriguez G.G. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob. Agents Chemother. 34:1990;40-43.
138. Gentry L.O., Rodriguez-Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob. Agents Chemother. 35:1991;538-541.
139. Mader J.T., Cantrell J.S., Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J. Bone Joint Surg. 72A:1990;104-110.
140. Drancourt M., Stein A., Argenson J.N., Zannier A., Curvale G., Raoult D. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob. Agents Chemother. 37:1993;1214-1218.
141. Brouqui P., Rousseau M.C., Stein A., Drancourt M., Raoult D. Treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Antimicrob. Agents Chemother. 39:1995;2423-2425.
142. Darmstadt G.L. Oral antibiotic therapy for uncomplicated bacterial skin infections in children. Pediatr. Infect. Dis. J. 16:1997;227-240.
143. D.C. Hooper, J.S. Wolfson, Treatment of skin and soft tissue infections with quinolone antimicrobial agents, in: J.S. Wolfson, D.C. Hooper, (Eds.), Quinolone Antimicrobial Agents, American Society for Microbiology, Washington, DC, 1989, pp. 233-242.
144. Gentry L.O., Ramirez-Ronda C.H., Rodriguez-Noriega E., Thadepalli H., del R.P., Ramirez C. Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections. A multicenter trial. Arch. Intern. Med. 149:1989;2579-2583.
145. Gentry L.O., Rodriguez-Gomez G., Zeluff B.J., Khoshdel A., Price M. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am. J. Med. 87:1989;57S-60S.
146. Peterson L.R., Lissack L.M., Canter K., Fasching C.E., Clabots C., Gerding D.N. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am. J. Med. 86:1989;801-808.
147. Caputo G.M., Cavanagh P.R., Ulbrecht J.S., Gibbons G.W., Karchmer A.W. Assessment and management of foot disease in patients with diabetes. New Engl. J. Med. 331:1994;854-860.
148. Raz R., Boger S. Long-term prophylaxis with norfloxacin versus nitrofurantoin in women with recurrent urinary tract infection. Antimicrob. Agents Chemother. 35:1991;1241-1242.
149. P. Ginés, A. Rimola, R. Planas, V. Vargas, F. Marco, Almela, M. Forne, M.L. Miranda, J. Llach, J.M. Salmeron, Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial, Hepatology 12 (1990) 716-724.
150. D.J. Winston, Use of quinolone antimicrobial agents in immunocompromised patients, in: D.C. Hooper, J.S. Wolfson (Eds.), Quinolone Antimicrobial Agents, American Society for Microbiology, Washington, DC, 1993, pp. 435-471.
151. Dekker A.W., Rozenberg-Arska M., Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann. Intern. Med. 106:1987;7-11.
152. Liang R.H., Yung R.W., Chan T.K., Chau P.Y., Lam W.K., So S.Y., Todd D. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob. Agents Chemother. 34:1990;215-218.
153. Bow E.J., Mandell L.A., Louie T.J., Feld R., Palmer M., Zee B., Pater J. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. Ann. Intern. Med. 125:1996;183-190.
154. Kotilainen P., Huovinen S., Jarvinen H., Aro H., Huovinen P. Epidemiology of the colonization of inpatients and outpatients with ciprofloxacin-resistant coagulase-negative staphylococci. Clin. Infect. Dis. 21:1995;685-687.
155. Kern W.V., Andriof E., Oethinger M., Kern P., Hacker J., Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob. Agents Chemother. 38:1994;681-687.
156. Dworzack D.L., Sanders C.C., Horowitz E.A., Allais J.M., Sookpranee M., Sanders W.E.J., Ferraro F.M. Evaluation of single-dose ciprofloxacin in the eradication of Neisseria meningitidis from nasopharyngeal carriers. Antimicrob. Agents Chemother. 32:1988;1740-1741.
157. O.H. Gilja, A. Halstensen, A. Digranes, H. Mylvaganam, Aksnes, E.A. Hoiby, Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis, Antimicrob. Agents Chemother. 37 (1993) 2024-2026.
158. Cuevas L.E., Kazembe P., Mughogho G.K., Tillotson G.S., Hart C.A. Eradication of nasopharyngeal carriage of Neisseria meningitidis in children and adults in rural Africa: a comparison of ciprofloxacin and rifampicin. J. Infect. Dis. 171:1995;728-731.
159. D.C. Hooper, J.S. Wolfson, Mechanisms of bacterial resistance to quinolones, in: D.C. Hooper, J.S. Wolfson (Eds.), Quinolone Antimicrobial Agents, American Society for Microbiology, Washington, DC, 1993, pp. 97-118.
160. Breines D.M., Ouabdesselam S., Ng E.Y., Tankovic J., Shah S., Soussy C.J., Hooper D.C. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of parE gene encoding a subunit of topoisomerase IV. Antimicrob. Agents Chemother. 41:1997;175-179.
161. Ng E.Y., Trucksis M., Hooper D.C. Quinolone resistance mutations in topoisomerase IV: relationship of the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1996;1881-1888.
162. Ferrero L., Cameron B., Manse B., Lagneaux D., Crouzet J., Famechon A., Blanche F. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:1994;641-653.
163. Willmott C.J., Maxwell A. A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob. Agents Chemother. 37:1993;126-127.
164. Cambau E., Gutmann L. Mechanisms of resistance to quinolones. Drugs. 45:(Suppl. 3):1993;15-23.
165. Ferrero L., Cameron B., Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1995;1554-1558.
166. Belland R.J., Morrison S.G., Ison C., Huang W.M. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol. Microbiol. 14:1994;371-380.
167. Okusu H., Ma D., Nikaido H. AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants. J. Bacteriol. 178:1996;306-308.
168. Poole K., Tetro K., Zhao Q.X., Neshat S., Heinrichs D.E., Bianco N. Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrob. Agents Chemother. 40:1996;2021-2028.
169. Ariza R.R., Cohen S.P., Bachhawat N., Levy S.B., Demple B. Repressor mutations in the marRAB operon that activate oxidative stress genes and multiple antibiotic resistance in Escherichia coli. J. Bacteriol. 176:1994;143-148.
170. Levy S.B. Active efflux mechanisms for antimicrobial resistance. Antimicrob. Agents Chemother. 36:1992;695-703.
171. Ng E.Y., Trucksis M., Hooper D.C. Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. 38:1994;1345-1355.
172. Neyfakh A.A. The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein. Antimicrob. Agents Chemother. 36:1992;484-485.
173. Jacoby G.A., Archer G.L. New mechanisms of bacterial resistance to antimicrobial agents. New Engl. J. Med. 324:1991;601-612.
174. Yonezawa M., Takahata M., Matsubara N., Watanabe Y., Narita H. DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1995;1970-1972.
175. Yoshida T., Muratani T., Iyobe S., Mitsuhashi S. Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 38:1994;1466-1469.
176. Yoshida H., Nakamura M., Bogaki M., Nakamura S. Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34:1990;1273-1275.
177. Høiby N., Jarlov J.O., Kemp M., Tvede M., Bangsborg J.M., Kjerulf A., Pers C., Hansen H. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet. 349:1997;167-169.
178. Blumberg H.M., Rimland D., Kiehlbauch J.A., Terry P.M., Wachsmuth I.K. Epidemiologic typing of Staphylococcus aureus by DNA restriction fragment length polymorphisms of rRNA genes: elucidation of the clonal nature of a group of bacteriophage-nontypeable, ciprofloxacin-resistant, methicillin-susceptible S. aureus isolates. J. Clin. Microbiol. 30:1992;362-369.
179. Fox K.K., Knapp J.S., Holmes K.K., Hook E.W. III, Judson F.N., Thompson S.E., Washington J.A., Whittington W.L. Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988-1994: the emergence of decreased susceptibility to the fluoroquinolones. J. Infect. Dis. 175:1997;1396-1403.
180. Tanaka M., Matsumoto T., Kobayashi I., Uchino U., Kumazawa J. Emergence of in vitro resistance to fluoroquinolones in Neisseria gonorrhoeae isolated in Japan. Antimicrob. Agents Chemother. 39:1995;2367-2370.
181. Smith S.M., Eng R.H.K., Bais P., Fan-Havard P., Tecson-Tumang F. Epidemiology of ciprofloxacin resistance among patients with methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 26:1990;567-572.
182. Alarcon T., Pita J., Lopez-Brea M., Piddock L.J. High-level quinolone resistance amongst clinical isolates of Escherichia coli and Klebsiella pneumoniae from Spain. J. Antimicrob. Chemother. 32:1993;605-609.
183. Ena J., Amador C., Martinez C., Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J. Urol. 153:1995;117-120.
184. Kern W.V., Markus A., Andriof E. Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. Eur. J. Clin. Microbiol. Infect. Dis. 13:1994;161-165.
185. Carratala J., Fernandez-Sevilla A., Tubau F., Dominguez M.A., Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob. Agents Chemother. 40:1996;503-505.
186. Bowler I.C.J.W., Connor M., Lessing M.P.A., Day D. Quinolone resistance and campylobacter species. J. Antimicrob. Chemother. 38:1996;315.
187. Van Dyck E., Crabbé F., Nzila N., Bogaerts J., Munyabikali J.P., Ghys P., Diallo M., Laga M. Increasing resistance of Neisseria gonorrhoeae in West and Central Africa consequences on therapy of gonococcal infection. Sex. Transm. Dis. 24:1997;32-37.
188. Gordon S.M., Carlyn C.J., Doyle L.J., Knapp C.C., Longworth D.L., Hall G.S., Washington J.A. The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: epidemiology and risk factors. Ann. Intern. Med. 125:1996;465-470.